Yoga improves mood, fatigue, and insomnia in cancer survivors following treatment
Dr Gwenaëlle Gravis speaks to ecancer about the interim results of the MOIO trial, an academic non-inferiority study on the use of immune checkpoint inhibitors (ICIs) at a reduced dosing frequency for patients with advanced cancer.
The study revealed a clinically significant imbalance in overall survival, suggesting that administering ICIs at a reduced frequency, every 12 weeks, is not recommended outside of clinical trials.
Dr Gravis highlights the need for further research into patient selection.
Yoga improves mood, fatigue, and insomnia in cancer survivors following treatment
Machine learning models improve prediction of immunotherapy outcomes across multiple cancer types
MCED blood test demonstrates high specificity, strong predictive value, and increased early cancer detection
Expectations and priorities of older patients with cancer: the PRIORITY multicenter cohort study
Alternative livelihood training programme for rural women who are employed in the tobacco industry in India